Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Blood and lymphatic system disorders – page 19

  • 1 201 clinical trials
  • 458 recruiting
  • 364 conditions
  • 27 countries

Conditions in this area

364 conditions with trials, the busiest first

Plasma cell myeloma164Acute myeloid leukaemia132Chronic lymphocytic leukaemia77Myelodysplastic syndrome53Diffuse large B-cell lymphoma51Acute lymphocytic leukaemia43Follicular lymphoma41Plasma cell myeloma refractory41Mantle cell lymphoma32Myelofibrosis31Chronic myeloid leukaemia29B-cell small lymphocytic lymphoma28Immune thrombocytopenia27B-cell lymphoma25Factor VIII deficiency25Sickle cell disease25Hodgkin's disease23Non-Hodgkin's lymphoma22Haematological malignancy20Marginal zone lymphoma17B-cell lymphoma refractory16B-cell type acute leukaemia16Paroxysmal nocturnal haemoglobinuria16Diffuse large B-cell lymphoma refractory14+340

Clinical trials in Blood and lymphatic system disorders

1 201 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 201 clinical trials

Thalassaemia

Recruiting

Study on the Safety and Effectiveness of CTX001 for Children with Transfusion-Dependent Beta-Thalassemia Using Exagamglogene Autotemcel and a Drug Combination

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Busulfan
  • Sponsor:Vertex Pharmaceuticals Inc.

Acute myeloid leukaemia

Recruiting

Study on Teicoplanin for Preventing Infections in Children with Acute Myeloid Leukemia

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Teicoplanin
  • Sponsor:Princess Maxima Center For Pediatric Oncology

T-cell type acute leukaemia+1

Recruiting

Study on the Safety and Effectiveness of OC-1 Therapy for Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or Lymphoma

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Autologous T-Cells Ex Vivo Modified With A Lentiviral Vector Encoding A Chimeric Antigen Receptor Specific For Cd1A
  • Sponsor:Onechain Immunotherapeutics S.L.

Acute lymphocytic leukaemia+2

Recruiting

Long-term Safety Study of AUTO4 and Rituximab in Patients with Potential Malignancy Treated with Autologous CAR T Cell Therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Auto4
  • Sponsor:Autolus Limited

Peripheral T-cell lymphoma unspecified

Recruiting

Study on the Effectiveness and Safety of Belinostat and Pralatrexate with Drug Combination for Newly Diagnosed Peripheral T-Cell Lymphoma Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Belinostat
  • Sponsor:Acrotech Biopharma Inc.

Chronic lymphocytic leukaemia

Recruiting

Study on Acalabrutinib for Adults with Chronic Lymphocytic Leukemia and Heart Issues

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:AstraZeneca AB

Mantle cell lymphoma

Recruiting

Study on Glofitamab, Venetoclax, and Zanubrutinib for Patients with Untreated or Relapsed High-Risk Mantle Cell Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Glofitamab
  • Sponsor:LYSARC

Plasma cell myeloma

Recruiting

Study on Reducing Oral Side Effects of Talquetamab in Multiple Myeloma Patients Using Pregabalin, Dexamethasone, and Clonazepam

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Clonazepam
  • Sponsor:Janssen Cilag International

Plasma cell myeloma

Recruiting

Study on the Safety and Efficacy of Cevostamab with Lenalidomide or Iberdomide for Patients with High-Risk or Relapsed Multiple Myeloma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cevostamab
  • Sponsor:F. Hoffmann-La Roche AG

Chronic lymphocytic leukaemia

Recruiting

Study of Ibrutinib for Treating Autoimmune Hemolytic Anemia in Patients with Chronic Lymphocytic Leukemia or Similar Conditions

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

T-cell type acute leukaemia

Recruiting

Study on the Safety and Effectiveness of Isatuximab and Drug Combination for Adults with Relapsed or Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Goethe University Frankfurt

Myelodysplastic syndrome

Recruiting

Study on the Safety and Effects of ION440 for Patients with MECP2 Duplication Syndrome

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ion440
  • Sponsor:Ionis Pharmaceuticals Inc.

Substances studied in this area

The therapies tested most often in Blood and lymphatic system disorders trials.

Dexamethasone139 clinical trialsRituximab122 clinical trialsVenetoclax114 clinical trialsCyclophosphamide100 clinical trialsLenalidomide98 clinical trialsCytarabine77 clinical trialsDaratumumab74 clinical trialsAzacitidine65 clinical trialsBortezomib64 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.